
In Entwicklung
Gesundheit·23.6.2026KI-Zusammenfassung
Eli Lilly's Experimental Obesity Drug Retatrutide Granted to Single Patient via Compassionate Use
A single 79-year-old patient received early access to Eli Lilly's experimental obesity drug retatrutide through the FDA's compassionate use program. The unusual case has sparked speculation about the patient's identity, with questions raised if it could be former President Donald Trump.
A
Ars Technica3 Min. Lesezeit